Shares cratered as INLIF Limited, a small Chinese manufacturer of robotic arms for injection molding machines, announced its second reverse stock split of 2026 — this time at a staggering 1-for-200 ratio — raising urgent questions about whether the company can survive as a public entity or is simply delaying an inevitable delisting.
Two Reverse Splits in 90 Days Signals a Company in Free Fall
INLIF's board approved a 1-for-200 reverse stock split of all authorized and issued ordinary shares , authorized by shareholders at an extraordinary general meeting in January and effective for trading on July 6, 2026. This follows a 1-for-16 consolidation effective April 6, 2026 — meaning the company is executing a combined 1-for-3,200 reduction in share count within a single quarter. The stock trades at just $0.06, down 99.6% over the past year from a 52-week high of $23. The first split bought barely two months of compliance before the price collapsed again.
The Nasdaq $1.00 Rule Is a Ticking Clock
Nasdaq mandates that a company's stock maintain a minimum bid price of $1.00 per share.
INLIF received a deficiency notice in October 2025 , used the April split to briefly clear the bar — maintaining a closing bid of $1.00 or higher for 10 consecutive days from April 8 to April 21 — then plunged right back. At $0.03, the 1-for-200 ratio would theoretically reset the price to roughly $6.00, but history suggests this bump may not hold.
The Math After the Split Leaves a Micro-Cap Shell
Post-split, outstanding Class A shares will shrink to just 1,046,875 and Class B to 3,906 , creating an extraordinarily thin float prone to wild swings. The company posted a loss per share of $5.26 over the last twelve months and remains unprofitable, though it holds more cash than debt.
Corporate PR Doesn't Match the Market's Verdict
INLIF called the split "a proactive measure designed to enhance financial flexibility."
Shares fell 28.9% in after-hours trading , and the stock is now down another 7.3% to $0.03. Experts view the reverse split as a temporary measure, emphasizing that long-term viability hinges on executing a strategic pivot and improving financial performance. Without revenue growth or a credible turnaround plan, each successive split erodes what little investor trust remains.